Vycor Medical, Inc. VYCO
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -15.73% | 5.06% | -8.41% | 31.44% | 22.18% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -15.73% | 5.06% | -8.41% | 31.44% | 22.18% |
| Cost of Revenue | -9.00% | 7.20% | 41.00% | 68.21% | 130.40% |
| Gross Profit | -17.07% | 4.66% | -15.60% | 27.62% | 11.91% |
| SG&A Expenses | -6.46% | -10.07% | 0.14% | 10.08% | 2.13% |
| Depreciation & Amortization | 0.00% | -6.04% | 0.00% | 0.00% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -7.59% | -8.13% | 4.01% | 13.08% | 14.12% |
| Operating Income | -86.50% | 457.81% | -289.12% | 191.45% | 215.43% |
| Income Before Tax | -174.32% | 152.21% | -831.34% | 108.36% | 357.00% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -174.32% | 152.21% | -831.34% | 108.36% | 357.00% |
| Earnings from Discontinued Operations | -77.78% | -- | -200.00% | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -193.31% | 152.07% | -835.82% | 108.19% | 339.00% |
| EBIT | -86.50% | 457.81% | -289.12% | 191.45% | 215.43% |
| EBITDA | -67.82% | 1,763.64% | -156.35% | 347.42% | 107.52% |
| EPS Basic | -200.00% | 28.33% | -850.00% | 29.85% | 333.33% |
| Normalized Basic EPS | -180.00% | 157.14% | -1,100.00% | 109.09% | 350.00% |
| EPS Diluted | -216.67% | 28.33% | -850.00% | 29.85% | 300.00% |
| Normalized Diluted EPS | -200.00% | 157.14% | -1,100.00% | 109.09% | 300.00% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | -0.01% | 1.43% | 2.28% |
| Average Diluted Shares Outstanding | -13.69% | 0.00% | -0.01% | 1.43% | 18.51% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |